These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6092955)

  • 1. What are we going to do about AIDS and HTLV-III/LAV infection?
    Merigan TC
    N Engl J Med; 1984 Nov; 311(20):1311-3. PubMed ID: 6092955
    [No Abstract]   [Full Text] [Related]  

  • 2. HTLV III infection and AIDS.
    Bingham JS
    Practitioner; 1985 Oct; 229(1408):869-75. PubMed ID: 2997767
    [No Abstract]   [Full Text] [Related]  

  • 3. Key epidemiologic questions about AIDS and infection with HTLV-III/LAV.
    Hopkins DR
    Public Health Rep; 1986; 101(3):234-7. PubMed ID: 3012620
    [No Abstract]   [Full Text] [Related]  

  • 4. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I, -II, -III).
    Fischinger PJ; Robey WG; Koprowski H; Gallo RC; Bolognesi DP
    Cancer Res; 1985 Sep; 45(9 Suppl):4694s-4699s. PubMed ID: 2410115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AIDS and the spectrum of HTLV-III/LAV infection.
    Pinching AJ; Weiss RA
    Int Rev Exp Pathol; 1986; 28():1-44. PubMed ID: 2870992
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunological properties of HTLV-III antigens recognized by sera of patients with AIDS and AIDS-related complex and of asymptomatic carriers of HTLV-III infection.
    Sarngadharan MG; diMarzo Veronese F; Lee S; Gallo RC
    Cancer Res; 1985 Sep; 45(9 Suppl):4574s-4577s. PubMed ID: 2410106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Case reports of 77 HTLV III/LAV-positive patients observed during one-year period. Preliminary note].
    Soranzo ML; Salassa B; Daziano E; Paggi GC
    Minerva Med; 1986 May; 77(20):897-900. PubMed ID: 3014379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proof of diaplacental transmission of HTLV III/LAV before the 20th week of pregnancy].
    Schäfer A; Jovaisas E; Stauber M; Löwenthal D; Koch MA
    Geburtshilfe Frauenheilkd; 1986 Feb; 46(2):88-9. PubMed ID: 3007265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1986 May; 35(20):334-9. PubMed ID: 3010072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [LAV/HTLV-III--new discoveries on its properties, isolation, vaccination and therapy].
    Asjö B; Morfeldt-Månson L; Fenyö EM; Böttiger B; Biberfeld G; Espmark A
    Lakartidningen; 1985 May; 82(20):1870-5. PubMed ID: 2987633
    [No Abstract]   [Full Text] [Related]  

  • 11. AIDS: the significance of anti-HTLV-III antibodies.
    Robinson PA; Brough J; Haddy L; Belshe RB; Khakoo R; Stevenson MM
    W V Med J; 1985 Sep; 81(9):194-7. PubMed ID: 2998098
    [No Abstract]   [Full Text] [Related]  

  • 12. HTLV-III/LAV and the origin and pathogenesis of AIDS.
    Gallo RC; Robert-Guroff M; Wong-Staal F; Reitz MS; Arya SK; Streicher HZ
    Int Arch Allergy Appl Immunol; 1987; 82(3-4):471-5. PubMed ID: 3032803
    [No Abstract]   [Full Text] [Related]  

  • 13. Testing for HTLV-III/LAV antibody.
    Holston JL
    Ala J Med Sci; 1986 Jul; 23(3):269-71. PubMed ID: 3019171
    [No Abstract]   [Full Text] [Related]  

  • 14. AIDS: the search for clues.
    WHO Chron; 1985; 39(6):207-11. PubMed ID: 3012884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seroepidemiological evidence for HTLV-III infection as the primary etiologic factor for acquired immunodeficiency syndrome.
    Sarngadharan MG; Schüpbach J; Bruch L; Devico A; Markham PD; Wong-Staal F; Gallo RC
    Prog Clin Biol Res; 1985; 182():309-27. PubMed ID: 2994105
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hospital hygiene. Notice of the Expert Federal Commission for AIDS on procedures to adopt in regard to patients with AIDS and to persons carrying anti-LAV/HTLV-III antibodies].
    Krankenpfl Soins Infirm; 1986 May; 79(5):74-5. PubMed ID: 3012197
    [No Abstract]   [Full Text] [Related]  

  • 17. Subunit vaccines against exogenous retroviruses: overview and perspectives.
    Hunsmann G
    Cancer Res; 1985 Sep; 45(9 Suppl):4691s-4693s. PubMed ID: 2410114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pathogenic retrovirus (HTLV-III) linked to AIDS.
    Broder S; Gallo RC
    N Engl J Med; 1984 Nov; 311(20):1292-7. PubMed ID: 6208484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.
    Ruscetti FW; Mikovits JA; Kalyanaraman VS; Overton R; Stevenson H; Stromberg K; Herberman RB; Farrar WL; Ortaldo JR
    J Immunol; 1986 May; 136(10):3619-24. PubMed ID: 2422259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Activation of the macrophage/lymphocyte system in AIDS, ARC and AIDS risk groups].
    Wachter H; Blecha HG; Fuchs D; Hausen A; Hengster P; Hinterhuber H; Reibnegger G; Reissigl H; Rössler H; Schönitzer D
    Wien Klin Wochenschr; 1986 Jul; 98(14):449-54. PubMed ID: 3019018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.